Zymeworks saw no growth in patent filings and highest growth of 1.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 1.99%. GlobalData’s DataBook provides a comprehensive analysis of Zymeworks‘s patent filings and grants. Buy the databook here.
Zymeworks has been focused on protecting inventions in United States(US) with four publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 100% filings and 100% grants. The United States(US) patent Office are among the top ten patent offices where Zymeworks is filings its patents. Among the top granted patent authorities, Zymeworks has 100% of its grants in United States(US).
Roche could be the strongest competitor for Zymeworks
Patents related to cell & gene therapy lead Zymeworks's portfolio
Zymeworks has the highest number of patents in cell & gene therapy. For cell & gene therapy, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Breast cancer related patents lead Zymeworks portfolio followed by cervical cancer, and kidney cancer (renal cell cancer)
Zymeworks has highest number of patents in breast cancer followed by cervical cancer, kidney cancer (renal cell cancer), bladder cancer, and nonmelanomatous skin cancer.
For comprehensive analysis of Zymeworks's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.